Researchers have announced that TAVALISSE® (fostamatinib disodium hexahydrate) has received regulatory approval in Brazil for treating adults with chronic immune thrombocytopenia (ITP) who did not respond well to previous treatments. This condition occurs when the immune system mistakenly destroys blood platelets, leading to excessive bruising and bleeding. The approval offers a new treatment option for patients at risk of serious complications due to low platelet counts.

This development is significant for individuals dealing with chronic ITP, as it provides a new avenue for managing their condition. In clinical trials, 18% of patients treated with fostamatinib achieved stable platelet responses, compared to just 2% on a placebo. Additionally, 43% of those on fostamatinib had at least one platelet count improvement within the first 12 weeks. This could mean better management of symptoms and a reduced risk of severe bleeding for those who struggle with existing therapies.

The evidence comes from two phase 3 clinical trials involving 150 participants, which showed promising results for fostamatinib. While these findings are encouraging, it’s important to note that they are based on a controlled setting, and further research will help confirm its long-term effectiveness and safety in broader populations. The drug is expected to be available in Brazil in late 2026, following its recent approval.

If you or someone you know is suffering from chronic ITP, it may be worth discussing this new treatment option with a healthcare provider once it becomes available. Always consult with a medical professional before making any changes to treatment plans.

Source: globenewswire.com